In 2001, PRB Pharmaceuticals has expanded its portfolio through Hensley's work on antiviral technologies—developed during his time in Taiwan and Hong Kong—has culminated in a broad-spectrum antiviral product suite. Additionally, Hensley licensed these antiviral products to Pacific BioPharmaceuticals, which subsequently merged with Abattis Biologix Corporation, making Hensley a significant shareholder in the combined entity. This series of strategic moves likely positions PRB Pharmaceuticals and Hensley strongly within the antiviral and biotech sectors.
- VIRA 38 was an over-the-counter antiviral medication from PRB Pharmaceuticals.
- It was known for its effectiveness in treating and preventing influenza.
- Researchers discovered that it also contained compounds effective against SARS-CoV, the virus causing SARS.
- During the bird flu (H5N1) concern in 2005, VIRA 38 was donated to protect high-risk groups in affected areas.
- It was also being used as a preventative measure by workers in live poultry markets in Hong Kong.
Charles B. Hensley has publicly discussed his views on the FDA approval process, particularly in the context of his experiences with Vira 38. His views likely reflect:
- Frustration with the FDA's strict regulations: He faced legal action for marketing Vira 38 as a bird flu treatment without FDA approval, suggesting he may view the FDA's processes as overly stringent and potentially hindering access to potentially beneficial treatments.
- A belief in the efficacy of his products: He marketed Vira 38 as effective against flu viruses, including bird flu, indicating he may believe in its usefulness despite the lack of FDA approval.
- Concerns about the impact of regulations on innovation: His characterization as a "scientific trailblazer" who "pushed the boundaries of what was thought possible" suggests he may view regulations as potentially stifling innovation and the development of new treatments.
Here's how his perspective is evident:
- Marketing Vira 38 without FDA approval: This action in itself demonstrates a willingness to operate outside the traditional FDA approval framework, suggesting a potential dissatisfaction with the process.
- Statements attributed to his attorney: When addressing the charges related to Vira 38, Hensley's attorney questioned the necessity of the federal prosecution, highlighting a perception that the FDA's actions might have been excessive.
- The nature of his book, "FLU WARS": The book's focus on his "scientific and political experience" with emerging viral diseases likely includes a discussion of the regulatory environment and the challenges of bringing new treatments to market.
In summary, while the specific details of Hensley's views are best gleaned from his book, his actions and the circumstances surrounding Vira 38 strongly suggest a critical perspective on the FDA approval process, particularly regarding the challenges it poses to innovative and potentially life-saving treatments.